Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) in the Treatment of Major Depressive Disorder

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult, outpatient with primary diagnosis of Major Depressive Disorder (depressive symptoms for at least 30 days prior to screening)~* Hamilton Psychiatric Rating Scale for Depression (HAM-D 17) total score of \>= 20~* Clinical Global Impressions Scale-Severity (CGI-S) score of \>= 4~Exclusion Criteria:~* Clinical instability - 25% or greater increase/decrease in HAM-D 17 total score from screening to baseline~* Significant risk of suicide as assessed by clinician judgement, HAM-D 17 and Columbia Suicide-Severity Rating Scale scores Other eligibility criteria also apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine succinate sustained-release 25 mg (Type: EXPERIMENTAL): None
- Desvenlafaxine succinate sustained-release 50 mg (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).